FilingSEC EDGAR8-K
REGENXBIO Receives FDA Clinical Hold on RGX-121 Clinical Trial
· SEC accepted
StageClinical Hold
Filing content
The company received notice of a clinical hold from the FDA for its RGX-121 trial following asymptomatic spine MRI findings, and does not expect to resubmit its BLA in the near term.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…